StockData
Bausch Health Companies Inc. logo

Bausch Health Companies Inc. (BHC) stock

BHCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026Score 7/3067% below fair value
$8.20−0.71 (-7.97%)

Close on Oct 30, 2026Market cap $3.07BP/E –Yield –

Earnings

Bausch Health Companies's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 17, 2027
Q4 FY2026 · estimated, after the close
Revenue, Q3 FY2026
$2.94B
+9.7% on a year earlier
Adjusted Earnings per Diluted Share, Q3 FY2026
$1.77
$0.48 a year earlier
Latest guidance
Raised
Oct 28, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Bausch Health Companies's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 17, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Oct 28, 2026after the close$2.94B+9.7%$1.15$1.77Release
Q2 FY2026ended Jun 30, 2026Jul 29, 2026after the close$2.85B+12.6%$0.68$1.26Release
Q1 FY2026ended Mar 31, 2026Apr 29, 2026after the close$2.52B+11.5%-$3.82$0.78Release
Q4 FY2025ended Dec 31, 2025Feb 18, 2026after the close$2.80B+9.4%-$0.30–Release
Q3 FY2025ended Sep 30, 2025Oct 29, 2025after the close$2.68B+6.8%$0.48–Release
Q2 FY2025ended Jun 30, 2025Jul 30, 2025after the close$2.53B+5.4%$0.40–Release
Q1 FY2025ended Mar 31, 2025Apr 30, 2025after the close$2.26B+5.1%-$0.16–Release
Q4 FY2024ended Dec 31, 2024Feb 19, 2025after the close$2.56B+6.2%$0.25–Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024after the close$2.51B+12.1%-$0.23–Release
Q2 FY2024ended Jun 30, 2024Aug 1, 2024before the open$2.40B+10.6%$0.03–Release
Q1 FY2024ended Mar 31, 2024May 2, 2024before the open$2.15B+10.8%-$0.17–Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Bausch Health Companies's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Revenue growth vs. Prior Yearnon-GAAPFY2026+4% – +6%+2% – +5%RaisedJul 29, 2026
RevenuesGAAPFY2026$10.98B – $11.18B$10.63B – $10.88BRaisedOct 28, 2026
Revenues (in Billions) B+LGAAPFY2026$5.44B – $5.54B$10.67B – $10.92BRaisedJul 29, 2026
Adj. EBITDA 1 growth vs. Prior Yearnon-GAAPFY2026+8% – +11%+3% – +5%RaisedJul 29, 2026
Adjusted EBITDAnon-GAAPFY2026$4.32B – $4.42B$3.88B – $4.00BRaisedOct 28, 2026
Adjusted EBITDA 1 (in Billions) BHC (excl. B+L)non-GAAPFY2026$3.03B – $3.10B$3.89B – $4.01BLoweredJul 29, 2026
Adjusted Cash Flows from Operations 1 (in Billions)non-GAAPFY2026$1.40B – $1.48B–NewJul 29, 2026
Adjusted Cash Flow from Operations (in Billions)non-GAAPFY2026$1.20B – $1.28B–NewApr 29, 2026
Adjusted Operating Cash Flow 1 (in Billions)non-GAAPFY2026$1.20B – $1.28B–NewFeb 18, 2026

Guidance vs results

The last range Bausch Health Companies gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025Revenue$10.05B – $10.25B$10.27BΣ4QAbove range
FY2025Revenue growth+3% – +6%+6.76%Σ4QAbove range

Guidance history

Every forecast Bausch Health Companies put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Oct 28, 2026Adjusted EBITDAFY2026$4.32B – $4.42BRaised
Oct 28, 2026RevenuesFY2026$10.98B – $11.18BRaised
Jul 29, 2026Adjusted EBITDA 1 (in Billions) BHC (excl. B+L)FY2026$3.03B – $3.10BLowered
Jul 29, 2026Adjusted EBITDA 1 (in Billions) B+LFY2026$1.03B – $1.08BLowered
Jul 29, 2026Adjusted EBITDA 1 (in Billions)FY2026$4.05B – $4.18BRaised
Jul 29, 2026Adj. EBITDA 1 growth vs. Prior YearFY2026+8% – +11%Raised
Jul 29, 2026Adjusted Cash Flows from Operations 1 (in Billions)FY2026$1.40B – $1.48BNew
Jul 29, 2026Revenues (in Billions) B+LFY2026$5.44B – $5.54BRaised
Jul 29, 2026Revenue growth vs. Prior YearFY2026+4% – +6%Raised
Jul 29, 2026Revenues (in Billions) BHC (excl. B+L)FY2026$5.35B – $5.50BLowered
Jul 29, 2026Revenues (in Billions)FY2026$10.79B – $11.04BRaised
Apr 29, 2026Adjusted EBITDA (in Billions)FY2026$3.89B – $4.01BNew
Apr 29, 2026Adj. EBITDA growth vs. Prior YearFY2026+3% – +5%New
Apr 29, 2026Adjusted Cash Flow from Operations (in Billions)FY2026$1.20B – $1.28BNew
Apr 29, 2026Revenues (in Billions)FY2026$10.67B – $10.92BNew
Apr 29, 2026Revenue growth vs. Prior YearFY2026+2% – +5%New
Feb 18, 2026Adjusted EBITDA 1 (in Billions)FY2026$3.88B – $4.00BNew
Feb 18, 2026Adjusted Operating Cash Flow 1 (in Billions)FY2026$1.20B – $1.28BNew
Feb 18, 2026Revenues (in Billions)FY2026$10.63B – $10.88BNew
Oct 29, 2025Adjusted EBITDA 1 (in Billions)FY2025$3.57B – $3.66BNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Bausch Health Companies filed with the SEC as exhibits to Form 8-K or 6-K

  1. BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2026 RESULTS, RAISES GUIDANCE
    Results
  2. BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE
    Results
  3. Michael Goettler Resigns from Bausch Health’s Board of Directors
    Update
  4. BAUSCH HEALTH ANNOUNCES FIRST QUARTER 2026 RESULTS
    Results
  5. BAUSCH HEALTH ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2025 RESULTS
    Results
  6. Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
    Update
  7. Bausch + Lomb Completes Refinancing of Outstanding
    News
  8. Bausch Health Announces Final Results and Expiration of Exchange Offers
    News
  9. Bausch + Lomb Announces Refinancing of Outstanding
    News
  10. Bausch Health Announces Early Exchange Offer Results for Exchange Offers
    News
  11. Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes
    News
  12. BAUSCH HEALTH ANNOUNCES THIRD QUARTER 2025 RESULTS
    Results
  13. Bausch Health Announces Increase in Shareholding by its Chairperson of the Board and Board Changes
    Update
  14. BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2025 RESULTS
    Results
  15. Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing
    News